Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD38 CAR-T cells (Zhujiang Hospital)
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD38 CAR-T cells (Zhujiang Hospital) is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Zhujiang Hospital for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves genetically modifying a patient's own T cells to express a CAR that specifically recognizes and binds to CD38, a glycoprotein frequently expressed on the surface of AML blasts. Upon binding to CD38, the CAR-T cells are activated to exert cytotoxic effects against the leukemic cells. This specific therapy is part of a broader clinical study evaluating multiple CAR-T targets (including CD33, CD56, and CD123) to address the heterogeneity of AML.
- Other names
- anti-CD38 chimeric antigen receptor T-cell therapyanti-CD-38 chimeric antigen receptor T-cell therapyanti-CD 38 chimeric antigen receptor T-cell therapyCD38-targeted CAR-T cellsCD-38-targeted CAR-T cellsCD 38-targeted CAR-T cells
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on anti-CD38 CAR-T cells (Zhujiang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD38 CAR-T cells (Zhujiang Hospital).